ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 65.2% | 67.6% | 90.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.5% | 34.4% | 22.9% | 1.4% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 34.6% | 2% | -25.6% | -65.6% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 46.4% | -10.9% | -42.8% | -88.5% |
| EPS Diluted | 0.81 | -0.13 | -0.43 | -0.61 |
| % Growth | 723.1% | 69.8% | 29.5% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |